BR112022025139A2 - Inibidores de egfr alostéricos e métodos de uso dos mesmos - Google Patents

Inibidores de egfr alostéricos e métodos de uso dos mesmos

Info

Publication number
BR112022025139A2
BR112022025139A2 BR112022025139A BR112022025139A BR112022025139A2 BR 112022025139 A2 BR112022025139 A2 BR 112022025139A2 BR 112022025139 A BR112022025139 A BR 112022025139A BR 112022025139 A BR112022025139 A BR 112022025139A BR 112022025139 A2 BR112022025139 A2 BR 112022025139A2
Authority
BR
Brazil
Prior art keywords
methods
allosteric
egfr inhibitors
allosteric egfr
inhibitors
Prior art date
Application number
BR112022025139A
Other languages
English (en)
Portuguese (pt)
Inventor
A Scott David
Gero Thomas
Beyett Tyler
Heppner David
E Gipson Krista
Huang Shih-Chung
Stroud Steve
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112022025139A2 publication Critical patent/BR112022025139A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022025139A 2020-06-09 2021-06-09 Inibidores de egfr alostéricos e métodos de uso dos mesmos BR112022025139A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036622P 2020-06-09 2020-06-09
US202063111429P 2020-11-09 2020-11-09
PCT/US2021/036657 WO2021252661A1 (en) 2020-06-09 2021-06-09 Allosteric egfr inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022025139A2 true BR112022025139A2 (pt) 2023-02-14

Family

ID=78846544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025139A BR112022025139A2 (pt) 2020-06-09 2021-06-09 Inibidores de egfr alostéricos e métodos de uso dos mesmos

Country Status (15)

Country Link
US (1) US20230212171A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161516A4 (cg-RX-API-DMAC7.html)
JP (3) JP7785701B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230033645A (cg-RX-API-DMAC7.html)
CN (1) CN115811977A (cg-RX-API-DMAC7.html)
AU (1) AU2021289729A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181982A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022019316A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22098041A (cg-RX-API-DMAC7.html)
IL (1) IL298935A (cg-RX-API-DMAC7.html)
JO (1) JOP20220332A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015739A (cg-RX-API-DMAC7.html)
SA (1) SA522441639B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021252661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
JP2025521540A (ja) * 2022-06-21 2025-07-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 縮合二環式egfr阻害剤およびその使用の方法
GB202216962D0 (en) 2022-11-14 2022-12-28 Addex Pharmaceuticals Sa Novel compounds
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005021963A1 (de) * 2005-05-12 2006-11-23 Aicuris Gmbh & Co. Kg Substituierte Dihydropyrazolotriazinone
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008130581A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
US8394802B2 (en) * 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
HK1252693A1 (zh) * 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
IL279800B2 (en) * 2018-06-29 2024-02-01 Hoffmann La Roche Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
CN112839937B (zh) * 2018-08-16 2023-08-22 韩国化学研究院 异吲哚啉-1-酮衍生物、其制备方法及其用途

Also Published As

Publication number Publication date
JP7785701B2 (ja) 2025-12-15
KR20230033645A (ko) 2023-03-08
ECSP22098041A (es) 2023-06-30
JP2025168374A (ja) 2025-11-07
AU2021289729A1 (en) 2023-02-02
MX2022015739A (es) 2023-03-23
CN115811977A (zh) 2023-03-17
NZ795548A (en) 2026-01-30
US20230212171A1 (en) 2023-07-06
WO2021252661A1 (en) 2021-12-16
CO2022019316A2 (es) 2023-01-16
EP4161516A1 (en) 2023-04-12
SA522441639B1 (ar) 2024-10-24
JP2023529701A (ja) 2023-07-11
IL298935A (en) 2023-02-01
JOP20220332A1 (ar) 2022-12-08
CA3181982A1 (en) 2021-12-16
EP4161516A4 (en) 2024-08-07
JP2025170326A (ja) 2025-11-18

Similar Documents

Publication Publication Date Title
SA522441639B1 (ar) Egfr مثبطات تفارغية وطرق استخدامها
BR112022009086A2 (pt) Inibidores alostéricos de egfr e métodos de uso dos mesmos
BR112021024810A2 (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer e método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112013010564A8 (pt) compostos heterocíclicos e usos dos mesmos
JOP20200277B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
MX387394B (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
BR112022014981A2 (pt) Inibidores de ectonucleotídeo pirofosfatase/fosfodiesterase 1 (enpp1) e métodos de uso dos mesmos
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
SA522441624B1 (ar) مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022011690A2 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer, método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas e invenção
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022009487A2 (pt) Compostos antagonistas do receptor de adenosina
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
BR112019023109A2 (pt) Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades